Incyte
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.About INCY
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas.
INCY Key Statistics
Stock Snapshot
As of today, Incyte(INCY) shares are valued at $117.36. The company's market cap stands at 23.47B, with a P/E ratio of 16.50.
During the trading session on 2026-07-22, Incyte(INCY) shares reached a daily high of $118.66 and a low of $116.27. At a current price of $117.36, the stock is +0.9% higher than the low and still -1.1% under the high.
Trading activity shows a volume of 213.51K, compared to an average daily volume of 1.6M.
The stock's 52-week range extends from a low of $67.20 to a high of $119.60.
The stock's 52-week range extends from a low of $67.20 to a high of $119.60.
INCY News
In July 2026, Halozyme Therapeutics announced a global collaboration and license agreement with Incyte to develop subcutaneous formulations of INCA033989, using...
William Blair analyst Matt Phipps has maintained their neutral stance on INCY stock, giving a Hold rating yesterday. Claim 55% Off TipRanks Unlock powerful inve...
H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Incyte today and set a price target of $140.00. Claim 55% Off TipRanks Unlock powerful invest...
Analyst ratings
55%
of 29 ratingsMore INCY News
New insider activity at Incyte ( (INCY) ) has taken place on July 20, 2026. Claim 55% Off TipRanks Unlock powerful investing tools with TipRanks Premium to make...
...
(RTTNews) - Biopharmaceutical company Halozyme Therapeutics, Inc. (HALO) announced Monday that it has entered into a global collaboration and license agreement...
Halozyme Therapeutics (HALO) announced that it has entered into a global collaboration and license agreement with Incyte (INCY) to evaluate additional subcutane...
Incyte (INCY) is back in focus after releasing detailed Phase 1/2 data for latarcibart in von Willebrand disease and flagging fresh oncology updates set for pre...
We wouldn't blame Incyte Corporation ( ) shareholders if they were a little worried about the fact that Steven Stein, the Executive VP recently netted about US$...
Incyte (NasdaqGS:INCY) reported new Phase 1/2 data for latarcibart (VGA039), a once monthly subcutaneous therapy for von Willebrand disease. The company highli...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.